What New Mounjaro Customers Actually Need to Know Before Starting

The decision that matters most: are you a suitable candidate?

Eligibility is where most new patients have the biggest questions, and it is worth being direct about it. The licensed indication covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition, such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. For some ethnic backgrounds, including South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, UK guidance applies a threshold 2.5 kg/m² lower throughout.

BMI alone does not decide anything. A prescriber looks at the full picture: your medical history, any medicines you take, and whether conditions such as a personal or family history of medullary thyroid cancer or a history of pancreatitis mean Mounjaro is not right for you. Pregnancy, breastfeeding, and trying to conceive are situations where Mounjaro is not recommended. People under 18 are outside the licensed age range. NICE's appraisal of tirzepatide (TA1026) sets out the NHS criteria in detail, though private providers assess against the broader licensed indication.

The consultation at nume is free, and a real prescriber reads your answers, not a decision algorithm. If you are suitable, treatment is confirmed the same day. If something in your history needs a closer look, a clinician will tell you directly. That transparency is the point of the assessment.

Choosing between Mounjaro and other licensed options

New patients often arrive having heard about several medicines: Mounjaro, Wegovy (semaglutide injection), and, as of June 2026, the newly approved oral Wegovy tablet. Choosing between them is a clinical decision, not a marketing one. If you are considering starting for the first time, it is also worth checking the new Mounjaro information at nume, which covers what has changed and what first-time patients should know. The main practical differences for someone starting out are the mechanism (Mounjaro acts on two receptors; semaglutide on one), the injection schedule (both are once weekly), and the trial evidence on average weight loss.

Head-to-head data from SURMOUNT-5, published in 2025, showed tirzepatide producing greater average weight reduction than semaglutide 2.4 mg over 72 weeks. That finding is relevant context, not a prescription. Side-effect profiles are broadly similar between the two injectables (mostly gastrointestinal in the early weeks) and individual tolerance varies. Someone who has tried semaglutide previously, or who wants to avoid injections entirely, will have different factors to weigh than someone starting fresh. The tirzepatide overview at nume goes into the mechanism in more depth if you want the science before your consultation.

What this decision really comes down to is a conversation with a prescriber who knows your history. No article can make it for you.

What the early weeks of treatment actually look like

The starting dose of 2.5 mg exists for one reason: to let your digestive system settle into the medicine gradually. Most people will not notice dramatic appetite changes in the first four weeks, and that is by design. Nausea, mild indigestion, or loose stools are common in the early stages, particularly after a dose step-up. They typically ease within days to a couple of weeks as your body adjusts.

Each pen contains four weekly doses. You inject subcutaneously (into the abdomen, thigh, or upper arm) rotating the site each week. Pens are stored in the fridge. For detailed storage windows and step-by-step injection guidance, the Patient Information Leaflet inside your pen is the definitive reference; never rely on a generic online guide for those specifics.

At nume, your pen arrives via DPD the next working day, tracked to your door, in plain unbranded packaging. There is nothing on the outside to indicate what is inside. The clinical aftercare team is available seven days a week if questions come up in those first weeks, because questions always do, and you can reach the Mounjaro customer service team directly if you need to speak to someone about your care. You can find more about what ongoing support looks like on the Mounjaro support page.

Cost, supply and what to check before committing

Private Mounjaro pricing reflects the fact that consultation, prescription, clinical oversight and delivery are all included in one figure. Eli Lilly raised the UK list price significantly from September 2025 (the highest-dose pen's list price moved from around £122 to around £330) so typical private prices since then range roughly £149 to £375 per month depending on dose and provider, as widely reported. The background on that price increase is worth reading before you compare providers, because headline prices vary partly because they include different things.

Before committing to any provider, verify them on the GPhC pharmacy register. A legitimate online pharmacy will appear there with a registration number you can look up. Sellers offering Mounjaro without a prescription, via social media, or at prices far below the market range are a serious red flag: the MHRA has warned repeatedly about counterfeit weight-loss pens, some containing insulin rather than tirzepatide. That risk is not theoretical.

If you are ready to find out whether Mounjaro is clinically right for you, our prescribers are available for a free consultation, and new patients can also take a look at the Mounjaro new customer offer to see what is available when you start. You can also read through frequently asked questions or explore the broader weight-loss treatment options at nume first.